## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (35% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($189.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. Are Options Traders Betting on a Big Move in BD Stock?**
- Source: TradingView â€” Track All Markets | 20251224T140810 | Neutral | Relevance: 100%
- Options traders are showing increased interest in Becton, Dickinson and Company (BDX) due to high implied volatility in its January 16, 2026 $225.00 Put options. This suggests expectations of a significant price movement in either direction, possibly driven by an upcoming event. Despite this, analysts currently have a "Hold" rating on BDX, with recent downward revisions to earnings estimates.

**2. Vontobel Holding Ltd. Lowers Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251225T111746 | Neutral | Relevance: 100%
- Vontobel Holding Ltd. significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 57.6% in the third quarter, selling over 200,000 shares. Despite this, other institutional investors increased their positions, and the company announced an increased quarterly dividend. Becton, Dickinson and Company has a current market capitalization of $55.88 billion and several analysts have recently updated their price targets and ratings.

**3. Tela Bio sues BD over hernia mesh monopoly claims**
- Source: Fierce Biotech | 20251224T010845 | Somewhat-Bearish | Relevance: 96%
- Tela Bio has filed a lawsuit against BD, alleging that the major medtech company has engaged in monopolistic practices to suppress competition in the hernia repair market. Tela Bio claims BD used conditional pricing and bundling contracts to prevent its OviTex mesh from being stocked, despite its competitive pricing compared to BD's Phasix line. BD denies the allegations, stating it operates fairly in a competitive industry.

**4. Becton, Dickinson and Company $BDX Shares Acquired by Covea Finance**
- Source: MarketBeat | 20251226T100947 | Somewhat-Bullish | Relevance: 95%
- Covea Finance has increased its stake in medical instruments supplier Becton, Dickinson and Company (NYSE:BDX) by 10.7%, acquiring 7,610 additional shares to hold a total of 78,847 shares valued at $14.76 million. Meanwhile, insiders have sold 978 shares worth approximately $186,725 in the last 90 days. The company recently raised its quarterly dividend to $1.05 per share, and analysts currently have a consensus "Hold" rating with a target price of $205.64 for BDX.

**5. Programmable Infusion Pumps And Catheters Market 2025- 2032**
- Source: openPR.com | 20251226T120917 | Bullish | Relevance: 95%
- This report from Coherent Market Insights details the Programmable Infusion Pumps And Catheters Market from 2025 to 2032, highlighting key insights, segmentation, and growth opportunities. It covers strategic investment hotspots, regional trends, and profiles major industry players like ICU Medical, Inc., Smiths Group plc., and Baxter International Inc. The study provides a comprehensive analysis of market structure, performance, and future developments, aiding decision-makers in navigating the evolving landscape.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.04M) |
| Sells | 5 ($0.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.4 |
| Current P/E | 13.1 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. Volume at 35% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.18% (CS: 51) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 1.038x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $196.30
- **Stop Loss:** $189.28 (3.6% risk)
- **Target:** $210.34 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 188
- **Position Value:** $36,904.40
- **Portfolio %:** 36.90%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*